|MDACC Study No:||2012-1091 (clinicaltrials.gov NCT No: NCT01742299)|
|Title:||An open label, multi-center imatinib roll-over protocol for patients who have completed a previous Novartis sponsored imatinib study and are judged by the investigator to benefit from continued imatinib treatment|
|Principal Investigator:||Jorge Cortes|
|Treatment Agent:||Gleevec; STI571|
|Study Description:||The goal of this clinical research study is to allow leukemia patients on |
Protocol DM99-232 or DM99-367 to continue receiving Gleevec (imatinib mesylate)
after those studies close. Researchers also want to collect long-term safety
data on patients receiving the drug.
Imatinib mesylate is designed to bind to certain proteins on the tumor cells,
which may prevent the cells from growing.